Compare Medpace Holdings Inc (MEDP) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Phillips 66 — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 6.7× Medpace Holdings Inc's market cap, and Phillips 66 pays a 1.8% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Phillips 66 for 62 Days on average.
| MEDP | PSX | |
|---|---|---|
Market Cap | $16.82B | $112.36B |
Volume | 223,093 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $630.19 | $281.60 |
52-Week Low | $393.42 | $126.76 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $16.44B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Phillips 66 (PSX) trades at $281.60, up 3.67% with strong technical momentum as it approaches resistance at $284. The stock shows robust fundamentals with three consecutive earnings beats and improving cash flow projections for 2026. Recent news highlights structural refining advantages and AI implementation for operational efficiency, supporting the bullish analyst consensus.
PSX offers attractive valuation with P/E of 16.07 and P/S of 0.75, coupled with strong profitability metrics including 24.02% ROE. Key risks include commodity price volatility and potential policy impacts on diesel exports. With 54% analyst buy ratings and $279 consensus target, the stock presents growth potential despite near-term overbought technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
